Description

Clinical trial outcomes for ALC in various types of dementia are summarized, presenting effect sizes from studies evaluating cognitive scales and psychometric test performance.

Figure 2

Chart

Source Paper

Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.

Nutrients (2020)

PMID: 32408706

DOI: 10.3390/nu12051389

Cite This Figure

![Figure 2: Clinical trial outcomes for ALC in various types of dementia are summarized, presenting effect sizes from studies evaluating cognitive scales and psychometric test performance.]()

> Source: Manuela Pennisi et al. "Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.." *Nutrients*, 2020. PMID: [32408706](https://pubmed.ncbi.nlm.nih.gov/32408706/)

<figure>
  <img src="" alt="Clinical trial outcomes for ALC in various types of dementia are summarized, presenting effect sizes from studies evaluating cognitive scales and psychometric test performance." />
  <figcaption>Figure 2. Clinical trial outcomes for ALC in various types of dementia are summarized, presenting effect sizes from studies evaluating cognitive scales and psychometric test performance.<br>  Source: Manuela Pennisi et al. "Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32408706/">32408706</a></figcaption>
</figure>

Related Evidence

Omega-3 Fatty Acids (DHA/EPA) for Age-Related Cognitive Decline

Grade A · 58 studies

Omega-3 Fatty Acids (DHA/EPA) for Mild Cognitive Impairment (MCI)

Grade B · 18 studies

Acetyl-L-Carnitine for Age-Related Cognitive Decline

Grade C · 14 studies